- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT02037828
Exhaled Breathing Condensate (EBC) Features and Lung Function Decline in Chinese Adults
The Screening and Confirmation of Protein Markers Which Can Predict the Decline of Lung Function of Chinese Adults in EBC (Exhaled Breathing Condensate )
Chronic obstructive lung disease (COPD) is a worldwide leading and still increasing cause of chronic morbidity and mortality. The important issue of COPD is its delayed diagnosis. Previous studies have found that accelerated loss of forced expiratory volume in 1 second (FEV1.0) in an individual is considered an indicator of developing COPD. This functional predictive system, due to lower sensitivity, is very difficult to discover high-risk population and earlier stage of the disease. The inflammation occurs earlier than the lung function impairment. Therefore, early detection of the inflammation may theoretically predict the occurrence of COPD and thus may guide early intervention.
Proteomics techniques and protein chip techniques provides us high throughput screening method to figure out characteristic inflammatory or metabolic markers of a diseases. It can be used for searching the biomarkers relating to lung function loss. EBC is collected from exhaled gas and is a good non-invasive method for exploring the pathologic process of the airways.
Thus we designed this study to identify potential biomarkers associated with rapid lung function decline. This study is divided into two parts: 1) screening potential biomarkers between stable COPD and healthy individuals; 2) verifying significant biomarkers of first part in a community-based nested case-control population for 2 years.
Panoramica dello studio
Stato
Condizioni
Descrizione dettagliata
Thus we designed this study. This study is divided into two parts: screening target biomarkers and identifying biomarkers.
- The FIRST STEP is a Case-control study to find target biomarkers. 20 COPD patients and 20 controls are to be enrolled in the study and their EBC and blood are collected. Proteomics techniques and protein chip techniques are to be used to screen COPD specific biomarkers in EBC.
- The SECOND STEP is a community-based nested case-control study to make sure whether the significant biomarkers in first part can predict rapid decline of lung function. The study will be a community based, multicenter prospective cohort designed, which including a total of 2,400 study subjects. EBC and blood are collected at the baseline and followed up for two years. Case group is defined as subjects with rapid decline of lung function and new COPD patients. Control group is selected according to 1:1 matching with age and gender.
Tipo di studio
Iscrizione (Anticipato)
Contatti e Sedi
Contatto studio
- Nome: Cheng Zhang, AR, MD
- Email: zhangcheng033@163.com
Luoghi di studio
-
-
Beijing
-
Beijing, Beijing, Cina, 100034
- Reclutamento
- Peking Universtiy First Hospital
-
Contatto:
- Zhou Tianyu, PHD
- Email: zty2712@hotmail.com
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
The FIRST STEP of study will be a outpatient based case-control study. 20 stable COPD patients and 20 healthy individuals will be recruited.
The SECOND STEP of study will be a community based, multi-center,prospective nested case-control designed, which including a total of 24OO study subjects, it will focus on two different communities, which are Shi Cha Hai community, De Sheng Community in Beijing
Descrizione
1. FIRST STEP:
Case Group:
Inclusion criteria
- age from 40 to 75 year olds; gender is not limited.
- Stable COPD
- Sign the informed consent with willingness of obeying the protocol. Exclusion criteria
- with known other chronic respiratory diseases except COPD (such as asthma, tuberculosis, bronchiectasis, interstitial lung disease, occupational lung diseases, sarcoidosis, lung cancer, et al);
- had been accepted lung lobectomy or transplantation;
- be ill with severe, or uncontrolled systemic diseases other than COPD (such as psychiatry diseases, chronic liver diseases, heart failure, auto-immunity diseases, chronic renal diseases, et al );
- Alcoholism, drug or solvents addition;
- Acute exacerbation COPD patients (AECOPD)
- Control group:
Inclusion criteria According to age (+ / - 5 years), gender and smoking, to match healthy volunteers as the control group.
- age from 40 to 75 year olds; gender is not limited.
- FEV1 /forced vital capacity (FVC)> 70% after inhaling bronchodilators;
- Sign the informed consent with willingness of obeying the protocol. Exclusion criteria
a. with known other chronic respiratory diseases except COPD (such as asthma, tuberculosis, bronchiectasis, interstitial lung disease, occupational lung diseases, sarcoidosis, lung cancer, et al); b. had been accepted lung lobectomy or transplantation; c. be ill with severe, or uncontrolled systemic diseases other than COPD (such as psychiatry diseases, chronic liver diseases, heart failure, auto-immunity diseases, chronic renal diseases, et al ); d. Alcoholism, drug or solvents addition; e. Acute respiratory infection in 4 weeks (rhinitis, pharyngitis, acute tracheobronchitis, pneumonia, etc.)
2.SECOND STEP: nested case-control study Inclusion criteria
- age from 40 to 75 year olds; gender is not limited.
- have been living in the community for more than 1 years and no plan to move in the near 3 years
- FEV1 / FVC > 70% after inhaling bronchodilators;
- Sign the informed consent with willingness of obeying the protocol.
Exclusion criteria
- with known other chronic respiratory diseases except COPD (such as asthma, tuberculosis, bronchiectasis, interstitial lung disease, occupational lung diseases, sarcoidosis, lung cancer, et al);
- had been accepted lung lobectomy or transplantation;
- be ill with severe, or uncontrolled systemic diseases other than COPD (such as psychiatry diseases, chronic liver diseases, heart failure, auto-immunity diseases, chronic renal diseases, et al );
- Alcoholism, drug or solvents addition;
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
Coorti e interventi
Gruppo / Coorte |
---|
Stable COPD in STEP1
no intervention
|
Control in STEP 1
no intervention
|
Case group in STEP 2
no intervention
|
Control group in STEP2
no intervention
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Protein biomarkers in EBC predicting rapid decline of lung function
Lasso di tempo: 4 years
|
The study(second part) is to identify the biomarkers screened from the first step and make sure which is associated with rapid decline of lung function.
The study will be a community based, multicenter prospective cohort designed, which including a total of 2,400 study subjects.
|
4 years
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Protein biomarkers of EBC between COPD patients and healthy individuals
Lasso di tempo: 1 year
|
The first part of study is to screen target biomarkers.
20 COPD patients and 20 controls are to be enrolled in the study and their EBC are to reserved.
Proteomics techniques and protein chip techniques were used to screening COPD specific biomarkers.
|
1 year
|
Blood biomarkers between COPD patients and healthy individuals
Lasso di tempo: 1 year
|
Peripheral blood will be collected.
Plasma and PBMC will be extracted and stored respectively.
|
1 year
|
Blood biomarkers predicting rapid decline of lung function
Lasso di tempo: 4 year
|
Peripheral blood will be collected.
Plasma and PBMC will be extracted and stored respectively.
|
4 year
|
Collaboratori e investigatori
Sponsor
Collaboratori
Investigatori
- Investigatore principale: Guangfa Wang, MD, PHD, Peking Universtiy First Hospital
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Anticipato)
Completamento dello studio (Anticipato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- PUCRP201303
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .